buprenorphine hcl and naloxone hcl
Generic: buprenorphine and naloxone
Labeler: avpakDrug Facts
Product Profile
Brand Name
buprenorphine hcl and naloxone hcl
Generic Name
buprenorphine and naloxone
Labeler
avpak
Dosage Form
TABLET
Routes
Active Ingredients
buprenorphine hydrochloride 2 mg/1, naloxone hydrochloride dihydrate .5 mg/1
Manufacturer
Identifiers & Regulatory
Product NDC
50268-144
Product ID
50268-144_47e23f4e-d4aa-7af1-e063-6394a90a2f05
Product Type
HUMAN PRESCRIPTION DRUG
Marketing Category
ANDA
Application Number
ANDA203136
DEA Schedule
ciii
Listing Expiration
2027-12-31
Marketing Start
2016-12-08
Pharmacologic Class
Classes
Normalized Code Variants
Searchable formats for this product NDC code
Digits Only
50268144
Hyphenated Format
50268-144
Supplemental Identifiers
RxCUI
UNII
Resolved Product View
Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.
Resolved Identity
Brand Name
buprenorphine hcl and naloxone hcl (source: ndc)
Generic Name
buprenorphine and naloxone (source: ndc)
Application Number
ANDA203136 (source: ndc)
Routes
source: ndc
Resolved Composition
Strengths
- 2 mg/1
- .5 mg/1
Packaging
- 50 BLISTER PACK in 1 BOX, UNIT-DOSE (50268-144-15) / 1 TABLET in 1 BLISTER PACK (50268-144-11)
Packages (1)
Ingredients (2)
Linked Drug Pages (1)
Raw FDA Data
View complete raw FDA NDC JSON payload
{"route": ["SUBLINGUAL"], "spl_id": "47e23f4e-d4aa-7af1-e063-6394a90a2f05", "openfda": {"unii": ["5Q187997EE", "56W8MW3EN1"], "rxcui": ["351266", "351267"], "spl_set_id": ["b955054b-b37d-4079-4fed-5939b763ecb4"], "manufacturer_name": ["AvPAK"]}, "finished": true, "packaging": [{"sample": false, "description": "50 BLISTER PACK in 1 BOX, UNIT-DOSE (50268-144-15) / 1 TABLET in 1 BLISTER PACK (50268-144-11)", "package_ndc": "50268-144-15", "marketing_start_date": "20161208"}], "brand_name": "Buprenorphine HCl and Naloxone HCl", "product_id": "50268-144_47e23f4e-d4aa-7af1-e063-6394a90a2f05", "dosage_form": "TABLET", "pharm_class": ["Opioid Antagonist [EPC]", "Opioid Antagonists [MoA]", "Partial Opioid Agonist [EPC]", "Partial Opioid Agonists [MoA]"], "product_ndc": "50268-144", "dea_schedule": "CIII", "generic_name": "Buprenorphine and Naloxone", "labeler_name": "AvPAK", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Buprenorphine HCl and Naloxone HCl", "active_ingredients": [{"name": "BUPRENORPHINE HYDROCHLORIDE", "strength": "2 mg/1"}, {"name": "NALOXONE HYDROCHLORIDE DIHYDRATE", "strength": ".5 mg/1"}], "application_number": "ANDA203136", "marketing_category": "ANDA", "marketing_start_date": "20161208", "listing_expiration_date": "20271231"}